MET and cancer: Amivantamab is a fully human EGFR-MET bispecific antibody that binds extracellularly to EGFR and MET to inhibit ligand binding, promote degradation of cell surface receptors, and activate the immune system via Fc-dependent trogocytosis and antibody-dependent cellular cytotoxicity.39 Because amivantamab binds extracellularly to EGFR and MET, it inhibits both pathways independent of their intracellular cancer-driving or treatment-acquired mutations.39 Additionally, amivantamab’s immune-activating effect distinguishes it from other EGFR inhibitors.39